Sanofi Opens Toronto Flu Vaccine Plant
Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026
The investment reinforces Sanofi's long-term vaccine manufacturing footprint and its partnership with Canadian governments, a modest positive for the company's growth narrative but unlikely to materially move its shares. It strengthens Canada's domestic biomanufacturing capacity and life sciences sector, with limited near-term impact on broader markets.
Sanofi inaugurated the Charles Best Building, a new flu vaccine manufacturing facility on its 52-acre Canada — Toronto campus, on September 16, 2026. The project represents a $925 million CAD investment, the single-largest biomanufacturing investment in Canadian history, with $415 million contributed by the Government of Canada and $55 million by the Government of Canada — Ontario. The facility will produce Fluzone High-Dose, Sanofi's high-potency influenza vaccine for adults aged 65 and older, and adds end-to-end vaccine manufacturing capacity on Canadian soil to strengthen preparedness for future flu pandemics. Construction broke ground in 2021 and the building is now fully operational; pending regulatory approval, production is expected to begin in early 2027 ahead of the 2027-28 flu season. The expansion is creating approximately 300 highly skilled biomanufacturing jobs. The inauguration was attended by Sanofi executives and Canadian officials including Industry Minister Mélanie Joly, Health Minister Marjorie Michel, Canada — Ontario Premier Doug Ford, and Canada — Toronto Mayor Olivia Chow. The facility is named after Charles Best, co-discoverer of insulin and an early medical director at what is now the Sanofi Canada — Toronto Campus. Sanofi, listed on Euronext and Nasdaq, is the largest biopharma manufacturer in Canada and distributes vaccines made in Canada — Toronto to more than 60 countries.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard